In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
ripples

RWE Market Impact on Medicines: A Lens for Pharma

IMS Health has developed the most comprehensive view of Real-World Evidence use and supply published to date. To learn how this could reshape your company's approach to evidence, click here

LATEST THINKING

Pricing & Market Access Outlook: 2012: Join our senior team as they share their perspectives on the key issues in IMSCG’s annual state of play in pricing and market access

New Paradigm - Incorporating Access Decisions Into Portfolio Strategy: Our Portfolio Strategy leadership presented this framework for value-based access strategy decisions at the recent 12th Annual Portfolio and Project Management for Pharma Conference in Barcelona.

Model Behaviour: IMSCG Principals Steven Flostrand and Raja Shankar look at the consequences of healthcare reforms across Europe, and identify how companies can successfully manage the new and more challenging healthcare funding environment.

The Big Sell: Biologics In Emerging Markets This paper published in Pharmaceutical Executive looks at the complex opportunities and access challenges that face commercialization of biologics in Africa, Asia, and Latin America.

 

Career

Supercharge your career in life sciences consulting.

 

Our insights are your competitive advantage.

IMS Consulting Group is the world’s leading, specialized advisor on critical business issues in life sciences.

With a global presence and local expertise across five continents, we know the pulse of the market – anticipating change, understanding its impact and resolving the challenges it brings. From pricing and market access and marketing issues to product, portfolio and geographic investment decisions – our life sciences consulting teams offer insights that drive results. All backed by the strongest evidence and analytics.

Brand & Commercial Strategy

Pharma growth rates will be the lowest ever through 2014. What questions should you address?

Geographic Investments

By 2014, pharmerging markets will drive 50% of global growth. How can you harness their potential?

HEOR & Real-World Evidence

'Prove it works' is now the new era. How to provide the evidence required to engage healthcare stakeholders?

Launch Excellence

Less than 1% of launches outperform. What does it take to be the best?

Pricing & Market Access

AMNOG has ended free pricing in Germany. What are the wider implications?


Strategy & Portfolio Analysis

Only 20% of medicines recoup the costs of development. How can you maximize return?